首页> 外文期刊>Blood purification >The Study of Low Calcium Dialysate on Elderly Hemodialysis Patients with Secondary Hypoparathyroidism
【24h】

The Study of Low Calcium Dialysate on Elderly Hemodialysis Patients with Secondary Hypoparathyroidism

机译:低钙透析液对继发性甲状旁腺功能低下的老年血液透析患者的研究

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: The study aimed to study the safety and efficacy of 1.25 mmol/l calcium dialysate on maintenance hemodialysis (MHD) in elderly patients who suffered from secondary hypoparathyroidism. Methods: Eighty-two elderly patients (ages >= 65) who had been in MHD with dialysate calcium at 1.5 mmol/l over 6 months and had 2 consecutive serum intact parathyroid hormone (iPTH) measurements at level below 100 pg/ml were selected and randomized into 2 groups: treatment group (41 patients, with dialysate calcium at 1.25 mmol/l) and control group (41 patients, still with dialysate calcium at 1.5 mmol/l). Both groups were studied for the duration of 12 months. The changes of serum iPTH, calcium, phosphorus, calcium and phosphorus product and other indicators as well as related adverse reactions were recorded at the following time points: before the study and 1, 3, 6 and 12 months into the study. In addition, the intimal media thickness (IMT) of carotid artery and abdominal aorta calcification score (AACS) were measured in the 0, 6 and 12 months during the study. Results: (1) In the treatment group, the levels of serum corrected calcium, phosphorus and calcium-phosphate product began to decline after 1 month and exhibited further decrease 3 months later. Serum iPTH level increased significantly after 1 month into the study and the trend continued. The above markers stabilized after month 6. Compared with pre-study markers, the changes of the above markers were significant after study (p < 0.05). (2) The aver-age IMT and AACS were evidently decreased during the 6 and 12 months of study in the treatment group. There was statistical significance (p < 0.05) when compared with the above indexes of the pre-study and the control group. (3) In the control group, there were no significant differences in above laboratory markers over the 12-month study period. (4) There was no significant difference in the adverse events observed between the 2 groups. Conclusion: Safety of low calcium dialysate (dialysate calcium 1.25 mmol/l) in elderly MHD patients with iPTH < 100 pg/ml is good, as well as improving carotid IMT, resistance index and AACS as indexes of vascular calcification in the small study group and warrants further investigation. (C) 2016 S. Karger AG, Basel
机译:目的:本研究旨在研究1.25 mmol / l透析液钙对继发性甲状旁腺功能减退的老年患者进行维持性血液透析(MHD)的安全性和有效性。方法:选择八十二名年龄≥65岁的MHD患者,在六个月内接受透析液钙浓度为1.5 mmol / l,并​​且连续两次进行血清完整甲状旁腺激素(iPTH)的测定,均低于100 pg / ml并随机分为2组:治疗组(41例,透析液钙浓度为1.25 mmol / l)和对照组(41例,仍以透析液钙浓度为1.5 mmol / l)。两组均进行了为期12个月的研究。在下列时间点记录血清iPTH,钙,磷,钙和磷产物的变化以及相关的不良反应:研究前和研究后1、3、6和12个月。此外,在研究过程中的第0、6和12个月中测量了颈动脉的内膜中层厚度(IMT)和腹主动脉钙化评分(AACS)。结果:(1)在治疗组中,血清校正钙,磷和磷酸钙产物的水平在1个月后开始下降,并在3个月后进一步下降。进入研究1个月后,血清iPTH水平显着升高,并且趋势持续。上述标记在第6个月后稳定下来。与研究前的标记相比,上述标记的变化在研究后具有显着性(p <0.05)。 (2)在治疗组的6个月和12个月的研究中,平均IMT和AACS明显降低。与研究前和对照组的上述指标相比,有统计学意义(p <0.05)。 (3)在对照组中,在12个月的研究期内,上述实验室指标无显着差异。 (4)两组之间观察到的不良事件没有显着差异。结论:在小研究组中,iPTH <100 pg / ml的老年MHD患者低钙透析液(透析液钙1.25 mmol / l)的安全性良好,并改善了颈动脉IMT,抵抗指数和AACS作为血管钙化的指标并需要进一步调查。 (C)2016 S.Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号